Phosphorylcholine Antibodies Preserve Cardiac Function and Reduce Infarct Size by Attenuating the Post-Ischemic Inflammatory Response

Phosphorylcholine monoclonal immunoglobulin G antibody attenuates the immediate post-ischemic inflammatory response by reducing the proinflammatory chemokine (C-C motif) ligand 2 chemokine and circulating Ly-6C(hi) monocytes. This subsequently enhances the post-ischemic repair process, resulting in...

Descripción completa

Detalles Bibliográficos
Autores principales: Pluijmert, Niek J., de Jong, Rob C.M., de Vries, Margreet R., Pettersson, Knut, Atsma, Douwe E., Jukema, J. Wouter, Quax, Paul H.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Preclinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775955/
https://www.ncbi.nlm.nih.gov/pubmed/33426378
http://dx.doi.org/10.1016/j.jacbts.2020.09.012
Descripción
Sumario:Phosphorylcholine monoclonal immunoglobulin G antibody attenuates the immediate post-ischemic inflammatory response by reducing the proinflammatory chemokine (C-C motif) ligand 2 chemokine and circulating Ly-6C(hi) monocytes. This subsequently enhances the post-ischemic repair process, resulting in limited adverse cardiac remodeling and preservation of cardiac function. Therefore, phosphorylcholine monoclonal immunoglobulin G antibody therapy may be a valid therapeutic approach against myocardial ischemia-reperfusion injury.

Ejemplares similares